GAO warns of unapproved AI chatbots in mental-health space
GAO's November 2026 spotlight says the FDA has not authorized any AI chatbot for mental-health care and notes two firms have only an accelerated-review designation.

The Government Accountability Office's Science & Technology Spotlight released in November 2026 highlights that the Food and Drug Administration has not granted marketing authorization for any artificial-intelligence chatbot intended to support mental-health care. The report notes two companies have advertised that their purpose-built chatbots received an FDA designation for accelerated review of narrow medical uses, but that designation does not guarantee future authorization.
Nearly one-fifth of Americans aged 12 to 21 reported using an AI chatbot for mental-health advice in 2025, according to the GAO. Experts caution that general-purpose chatbots are not designed for therapeutic purposes and can reinforce users' perspectives through "sycophantic" behavior. While some developers have added guardrails after incidents linking chatbots to self-harm, the GAO says certain guardrails may be ineffective and development may lag behind rapid technological change.
Purpose-built chatbots are described as programs trained on mental-health data and therapeutic techniques. Some developers claim their tools are based on established therapeutic approaches, and a few report ongoing or completed randomized controlled trials. The GAO stresses that high-quality studies are still needed before any chatbot could be considered a substitute for professional care.
The report identifies health-and-safety risks, privacy concerns from retained conversation data, and uncertain efficacy as key challenges. It calls for research to determine safe support mechanisms, for standards that mitigate risks while preserving potential benefits, and for clarification of accountability when negative outcomes occur. The GAO also notes that state and federal regulation of mental-health AI is evolving, and existing rules may not adequately address identified risks.
For further information, the GAO lists contacts and references, including GAO-24-106946 and GAO-25-107172, as well as recent advisory reports from the American Psychological Association and the National Academy of Medicine.
Further reading



